

## A Joint venture between Mundipharma and NTC

12 December 2017 | News

### Mundipharma acquires Middle East and Africa licensing and distribution rights for NTC's ophthalmology portfolio



Mundipharma is a network of independent associated companies, covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa.

Mundipharma has expanded its ophthalmology portfolio in the Middle East and Africa by agreeing a new commercial partnership with NTC.

NTC is an Italian pharmaceutical company with deep experience in research and development.

NTC's portfolio was developed to address unmet medical needs in the treatment of several ophthalmic diseases, including blepharitis, dry eye, allergies and glaucoma.

"The addition of the NTC medicines complements Mundipharma's current ophthalmology portfolio in the Middle East and Africa," said Mundipharma CEO, Raman Singh.

"It's another bold and important step in our efforts to establish market leadership in the region backed by a strong and diversified portfolio of medicines." He added

As well as licensing and distribution rights, under the partnership Mundipharma will also benefit from NTC's commitment to research and development in ophthalmology.

NTC operates an international ophthalmology research and development program called Italian Innovation.

Through the program, it engages with a large number of opinion leaders and clinical centres.

It will focus on developing novel therapeutic solutions, with rich clinical insights, to release better and more affordable therapeutic treatments for patients.

"As NTC's strategic partner in Middle East and Africa, Mundipharma can now leverage its world class development and clinical programs to improve clinical outcomes in ophthalmology," stated Mr Singh.

According to him, this is a great result for patients, who will benefit from improved access to more medicines with higher

therapeutic value.

“Partnering with a leading company like Mundipharma is of real value and importance to NTC as it confirms the importance of our development efforts in the ophthalmic area,” said Riccardo Carbucicchio, President and CEO, NTC.

“Mundipharma are an ideal strategic partner in the Middle East and Africa with the capability and expertise to extend the reach of these medicines to benefit more patients,” he added